全文获取类型
收费全文 | 34103篇 |
免费 | 2755篇 |
国内免费 | 477篇 |
专业分类
耳鼻咽喉 | 77篇 |
儿科学 | 859篇 |
妇产科学 | 495篇 |
基础医学 | 1809篇 |
口腔科学 | 189篇 |
临床医学 | 4595篇 |
内科学 | 4520篇 |
皮肤病学 | 249篇 |
神经病学 | 2169篇 |
特种医学 | 693篇 |
外国民族医学 | 1篇 |
外科学 | 1987篇 |
综合类 | 5504篇 |
现状与发展 | 2篇 |
一般理论 | 8篇 |
预防医学 | 10069篇 |
眼科学 | 140篇 |
药学 | 2209篇 |
42篇 | |
中国医学 | 460篇 |
肿瘤学 | 1258篇 |
出版年
2024年 | 20篇 |
2023年 | 529篇 |
2022年 | 668篇 |
2021年 | 1188篇 |
2020年 | 1530篇 |
2019年 | 1140篇 |
2018年 | 1068篇 |
2017年 | 1109篇 |
2016年 | 1078篇 |
2015年 | 1132篇 |
2014年 | 2745篇 |
2013年 | 2708篇 |
2012年 | 2512篇 |
2011年 | 2467篇 |
2010年 | 1996篇 |
2009年 | 1792篇 |
2008年 | 1911篇 |
2007年 | 1650篇 |
2006年 | 1491篇 |
2005年 | 1201篇 |
2004年 | 1051篇 |
2003年 | 1010篇 |
2002年 | 709篇 |
2001年 | 645篇 |
2000年 | 526篇 |
1999年 | 403篇 |
1998年 | 350篇 |
1997年 | 325篇 |
1996年 | 279篇 |
1995年 | 289篇 |
1994年 | 246篇 |
1993年 | 202篇 |
1992年 | 206篇 |
1991年 | 183篇 |
1990年 | 156篇 |
1989年 | 123篇 |
1988年 | 112篇 |
1987年 | 89篇 |
1986年 | 70篇 |
1985年 | 100篇 |
1984年 | 83篇 |
1983年 | 47篇 |
1982年 | 38篇 |
1981年 | 29篇 |
1980年 | 26篇 |
1979年 | 22篇 |
1978年 | 17篇 |
1977年 | 14篇 |
1976年 | 17篇 |
1975年 | 10篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
目的 探讨医院信息系统中增加住院陪护管理功能的应用效果。方法 基于互联网医院、智慧医院等信息系统,开发信息化住院陪护管理功能,包括流行病学史调查、免费核酸申请、电子陪护证办理、体温监测登记及上报和统计查询。该功能与医院智慧护理链接后全院应用。比较功能应用前和应用后的遵医嘱一患一陪达标率、有效陪护证达标率、体温监测并登记日上报达标率和陪护证使用追溯率,评价护士和管理者疫情防控管理的人均耗时以及对该管理功能的满意度。结果 应用信息化陪护管理功能后,一患一陪达标率、有效陪护证达标率、体温监测并登记日上报达标率和陪护证使用追溯率显著高于应用前(均P<0.05);护士陪护管理人均耗时从(554.13±30.77)s降至(311.67±21.54)s(P<0.05);护士和管理者对该信息化陪护管理功能的满意度显著提高(均P<0.05)。结论 信息化住院陪护管理功能的应用有效提升了疫情期间陪护的管理质量和管理效率,提高了一线护士和管理者的满意度。 相似文献
2.
Maja Popovic Gorana Matovina-Brko Masa Jovic Lazar S Popovic 《World journal of clinical oncology》2022,13(1):28-38
Renal cell cancer (RCC) represents 2%-3% of all adulthood cancers and is the most common malignant neoplasm of the kidney (90%). In the mid-nineties of the last century, the standard of treatment for patients with metastatic RCC was cytokines. Sunititib and pazopanib were registered in 2007 and 2009, respectively, and have since been the standard first-line treatment for metastatic clear cell RCC (mccRCC). Renal cell cancer is a highly immunogenic tumor with tumor infiltrating cells, including CD8+ T lymphocytes, dendritic cells, natural killer cells (NK) and macrophages. This observation led to the design of new clinical trials in which patients were treated with immunotherapy. With the growing evidence that proangiogenic factors can have immunomodulatory effects on the host’s immune system, the idea of combining angiogenic drugs with immunotherapy has emerged, and new clinical trials have been designed. In the last few years, several therapeutic options have been approved [immunotherapy and immunotherapy/tyrosine kinase inhibitors (TKI)] for the first-line treatment of mccRCC. Nivolumab/ipilimumab is approved for the treatment of patients with inter mediate and poor prognoses. Several checkpoint inhibitors (pembrolizumab, nivolumab, avelumab) in combination with TKI (axitinib, lenvatinib, cabozan tinib) are approved for the treatment of patients regardless of their International mRCC Database Consortium prognostic group and PD-L1 expression. There is no specific and ideal biomarker that could help in selecting the ideal patient for the appropriate first-line treatment. 相似文献
3.
4.
5.
XI Hui CHENG Guan Liang HU Fei Fei LI Song Nan DENG Xuan ZHOU Yong 《Biomedical and environmental sciences : BES》2022,35(3):206-214
Objective To explore associations between lipoprotein-associated phospholipase A2(Lp-PLA2) and the risk of cardiovascular events in a Chinese population, with a long-term follow-up.Methods A random sample of 2,031 participants(73.6% males, mean age = 60.4 years) was derived from the Asymptomatic Polyvascular Abnormalities Community study(APAC) from 2010 to 2011. Serum Lp-PLA2 levels were determined by enzyme-linked immunosorbent assay(ELISA). The composite endpoint was a combination of first-eve... 相似文献
6.
7.
基于预算的公立医院成本费用目标管理,兼具年度预算的资金管控与月度目标的执行进度管控,其信息系统设计的关键点是数据信息抓取、传递、回馈、监督,形成事前预算、事中分析执行、事后反馈的成本费用管控模式,实现提质、增效、降耗的管控目的,使公立医院的发展由“规模扩张”型的成长阶段平稳过渡到精细化、质量效益型的成本管理阶段。 相似文献
8.
Matthew C. Phillips Laura Sarff Josh Banerjee Chase Coffey Paul Holtom Steve Meurer Noah Wald-Dickler Brad Spellberg 《Journal of medical virology》2022,94(1):318-326
When hospitals first encountered coronavirus disease 2019 (COVID-19), there was a dearth of therapeutic options and nearly 1 in 3 patients died from the disease. By the summer of 2020, as deaths from the disease declined nationally, multiple single-center studies began to report declining mortality of patients with COVID-19. To evaluate the effect of COVID-19 on hospital-based mortality, we searched the Vizient Clinical Data Base for outcomes data from approximately 600 participating hospitals, including 130 academic medical centers, from January 2017 through December 2020. More than 32 million hospital admissions were included in the analysis. After an initial spike, mortality from COVID-19 declined in all regions of the country to under 10% by June 2020 and remained constant for the remainder of the year. Despite this, inpatient, all-cause mortality has increased since the beginning of the pandemic, even those without respiratory failure. Inpatient mortality has particularly increased in elderly patients and in those requiring intubation for respiratory failure. Since June 2020, COVID-19 kills one in every 10 patients admitted to the hospital with this diagnosis. The addition of this new disease has raised overall hospital mortality especially those who require intubation for respiratory failure. 相似文献
9.
10.
Brede H. Eschliman MPH Hongmai H. Pham MD PhD Amol S. Navathe MD PhD Karen M. Dale BSN MSN Julian Harris MD MBA 《Health services research》2023,58(Z3):311-317